Related references
Note: Only part of the references are listed.Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
Kelong Han et al.
NEURO-ONCOLOGY (2014)
Giant Cell Tumor of Bone in Childhood: Clinical Aspects and Novel Therapeutic Targets
Noah Federman et al.
PEDIATRIC DRUGS (2014)
U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma
Michael Axelson et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
Andrew D. Norden et al.
NEURO-ONCOLOGY (2013)
Velocity of tumor spontaneous expansion predicts long-term outcomes for diffuse low-grade gliomas
Johan Pallud et al.
NEURO-ONCOLOGY (2013)
Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Radiation Therapy and Concomitant Temozolomide: Comparison Study of Standard and High-b-Value Diffusion-weighted Imaging
Hee Ho Chu et al.
RADIOLOGY (2013)
Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks
Paul Blanche et al.
STATISTICS IN MEDICINE (2013)
Sunitinib malate for the treatment of renal cell carcinoma
Lori Wood
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Dynamic imaging response following radiation therapy predicts long-term outcomes for diffuse low-grade gliomas
Johan Pallud et al.
NEURO-ONCOLOGY (2012)
Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma
R. J. Young et al.
NEUROLOGY (2011)
Pseudoprogression Following Chemoradiotherapy for Glioblastoma Multiforme
Paul Sanghera et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2010)
A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation
Brian Thiessen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
James R. Perry et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide
Gregor Dresemann et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma
Wenting Wu et al.
NEURO-ONCOLOGY (2010)
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study
W. K. Alfred Yung et al.
NEURO-ONCOLOGY (2010)
Changes in Relative Cerebral Blood Volume 1 Month after Radiation-Temozolomide Therapy Can Help Predict Overall Survival in Patients with Glioblastoma
Rajiv Mangla et al.
RADIOLOGY (2010)
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results
Marta Santisteban et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression
Elizabeth R. Gerstner et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations
Cristo Chaskis et al.
SURGICAL NEUROLOGY (2009)
Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide
Walter Taal et al.
CANCER (2008)
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European organisation for research and treatment of cancer brain tumor group study
Eric Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
J. F. de Groot et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Endpoints for assessing drug activity in clinical trials
Richard Pazdur
ONCOLOGIST (2008)
Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma
Antje Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging
Alan Jackson et al.
CLINICAL CANCER RESEARCH (2007)
Dynamic history of low-grade gliomas before and after temozolomide treatment
Damien Ricard et al.
ANNALS OF NEUROLOGY (2007)
A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme
Morris D. Groves et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme
Michael A. Badruddoja et al.
NEURO-ONCOLOGY (2007)
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma:: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO)
A. A. Brandes et al.
BRITISH JOURNAL OF CANCER (2006)
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2006)
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study
Timothy F. Cloughesy et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme
V. A. Levin et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
PCV chemotherapy for recurrent glioblastoma
F Schmidt et al.
NEUROLOGY (2006)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastorna multiforme
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression
MCY de Wit et al.
NEUROLOGY (2004)
Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study
MD Prados et al.
NEURO-ONCOLOGY (2004)
Phase II study of Fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American brain tumor consortium study
VK Puduvalli et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
How effective is BCNU in recurrent glioblastoma in the modern era?: A phase II trial
AA Brandes et al.
NEUROLOGY (2004)
Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme
MC Chamberlain
JOURNAL OF NEURO-ONCOLOGY (2002)
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse
M Brada et al.
ANNALS OF ONCOLOGY (2001)
PCV chemotherapy for recurrent glioblastoma multiforme
AC Kappelle et al.
NEUROLOGY (2001)
Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatment
AJ Kumar et al.
RADIOLOGY (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
